Earnings Call Insights: Madrigal Pharmaceuticals (MDGL) Q3 2026
CEO William Sibold framed the quarter around accelerating demand and market expansion, saying, “The business is performing exceptionally well. Rezdiffra is growing rapidly, and the MASH market is accelerating.” He highlighted Q3 net sales of $431
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.